Y-mAbs Therapeutics, Inc. (YMAB) Social Stream
Y-mAbs Therapeutics Inc (YMAB) Price Targets From Analysts
Use the tables below to see what analysts covering Y-mAbs Therapeutics Inc think about its future price and what recommendations they have for investors and traders.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 152 days, YMAB's average price target has gone down $12.46.
Over the past 50 weeks, YMAB's average upside potential has been 87.42%.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
YMAB Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The Trend in the Broker Recommendations
YMAB's average broker recommendation rating worsened by 0.42 over the prior 17 months.
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for YMAB as an investment opportunity.
- In terms of how Y-mAbs Therapeutics Inc fares relative to all US stocks, note that its upside potential (average analyst target price relative to current price) is greater than 469.44% of that group.
- In terms of how Y-mAbs Therapeutics Inc fares relative to all US stocks, note that its variance in analysts' estimates is lower than -339.25% of that group.
- In the context of Pharmaceutical Products stocks, Y-mAbs Therapeutics Inc's average analyst price target is greater than 335.49% of them.
- Y-mAbs Therapeutics Inc's number of analysts covering the stock is greater than 188.45% of stocks in the mid market cap category.
What is the outlook for YMAB? Use POWR Ratings for clearer insight into price direction.